Predictors of Thrombohemorrhagic Early Death in Children and Adolescents with T(15;17)-positive Acute Promyelocytic Leukemia Treated with ATRA and Chemotherapy
Overview
Authors
Affiliations
Clinical trials on childhood acute promyelocytic leukemia (APL) report early death (ED) rates of 3-8%, but predictors of thrombohemorrhagic (TH)-ED are not well understood. In a retrospective study, we aimed to determine the incidence and predictors of TH-ED in childhood APL. Data were analyzed from children and adolescents with t(15;17)-positive APL (n = 683) who started treatment with all-trans retinoic acid (ATRA) and chemotherapy in different international studies. Demographic data; initial white blood cell (WBC), peripheral blood (PB) blast, and platelet counts; hemoglobin value; coagulation parameters; morphologic variant (M3 or M3v); and induction details were analyzed. Early death was defined as death occurring within 30 days of presentation. The incidence of ED was 4.7% (32 of 683 patients). Predictors of TH-ED were identified by univariable and multivariable Cox proportional hazard regression analyses (n = 25). In univariable analysis, high WBC (>10 × 10/L) (P < 0.001) and high PB blast (>30 × 10/L) (P < 0.001), M3v (P < 0.01), and black ethnicity (P < 0.001) were independent predictors of TH-ED. In multivariable analysis, high WBC count (P < 0.01) and obesity (i.e., body mass index ≥95th percentile for age) (P = 0.03) were predictors of TH-ED. Initial high WBC counts and obesity are likely predictors of TH-ED in childhood APL. The efficacy of novel drugs for APL-associated coagulopathy or of frontline arsenic trioxide and ATRA combination regimens in reducing ED rates in childhood APL remains to be established.
Silva W, Kim H, Undurraga M, Navarro-Cabrera J, Salinas V, Muxi P Haematologica. 2024; 110(3):795-798.
PMID: 39479861 PMC: 11873706. DOI: 10.3324/haematol.2024.286338.
Hermsen J, Hambley B Cancers (Basel). 2023; 15(13).
PMID: 37444587 PMC: 10340352. DOI: 10.3390/cancers15133477.
Karalexi M, Markozannes G, Tagkas C, Katsimpris A, Tseretopoulou X, Tsilidis K Diagnostics (Basel). 2022; 12(10).
PMID: 36292046 PMC: 9600212. DOI: 10.3390/diagnostics12102357.
Luo S, Tian J, Sun X, Wu F, Liu Y, Wan W Evid Based Complement Alternat Med. 2022; 2022:8314176.
PMID: 35836830 PMC: 9276483. DOI: 10.1155/2022/8314176.
Jabbar N, Khayyam N, Arshad U, Maqsood S, Hamid S, Mansoor N Indian J Hematol Blood Transfus. 2021; 37(4):569-575.
PMID: 34744341 PMC: 8523738. DOI: 10.1007/s12288-021-01404-1.